Literature DB >> 6381024

Current status of chemotherapy of breast cancer.

A Coates.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6381024     DOI： 10.2165/00003495-198428020-00001

Source DB:  PubMed          Journal:  Drugs        ISSN： 0012-6667            Impact factor:   9.546


× No keyword cloud information.
  37 in total

1.  Integration of chemotherapy into combined modality treatment of solid tumors VII. Adenocarcinoma of the breast.

Authors:  S K Carter
Journal:  Cancer Treat Rev       Date:  1976-09       Impact factor: 12.111

2.  Prospective evaluation of rotating chemotherapy in advanced breast cancer. An Eastern Cooperative Oncology Group Trial.

Authors:  D Tormey; R Gelman; G Falkson
Journal:  Am J Clin Oncol       Date:  1983-02       Impact factor: 2.339

3.  Adriamycin combinations in advanced breast cancer. A Southwest Oncology Group Study.

Authors:  B L Tranum; B McDonald; T Thigpen; C Vaughn; H Wilson; T Maloney; J Costanzi; J Bickers; N G el Mawli; R Palmer; B Hoogstraten; L Heilburn; S Rasmusen
Journal:  Cancer       Date:  1982-03-01       Impact factor: 6.860

4.  Surgical adjuvant chemotherapy: results with one short course with cyclophosphamide after mastectomy for breast cancer.

Authors:  R Nissen-Meyer; K Kjellgren; K Malmio; B Månsson; T Norin
Journal:  Cancer       Date:  1978-06       Impact factor: 6.860

5.  Combination chemotherapy (CMFVP) versus L-phenylalanine mustard (L-PAM) for operable breast cancer with positive axillary nodes: a Southwest Oncology Group Study.

Authors:  H Glucksberg; S E Rivkin; S Rasmussen; B Tranum; N Gad-el-Mawla; J Costanzi; B Hoogstraten; J Athens; T Maloney; J McCracken; C Vaughn
Journal:  Cancer       Date:  1982-08-01       Impact factor: 6.860

6.  Combined chemotherapy-radiotherapy approach in locally advanced (T3b-T4) breast cancer.

Authors:  M De Lena; R Zucali; G Viganotti; P Valagussa; G Bonadonna
Journal:  Cancer Chemother Pharmacol       Date:  1978       Impact factor: 3.333

7.  Adriamycin versus methotrexate in five-drug combination chemotherapy for advanced breast cancer: a randomized trial.

Authors:  H B Muss; D R White; F Richards; M R Cooper; J J Stuart; D V Jackson; L Rhyne; C L Spurr
Journal:  Cancer       Date:  1978-11       Impact factor: 6.860

8.  A randomized trial of five and three drug chemotherapy and chemoimmunotherapy in women with operable node positive breast cancer.

Authors:  D C Tormey; V E Weinberg; J F Holland; R B Weiss; O J Glidewell; M Perloff; G Falkson; H C Falkson; P H Henry; L A Leone
Journal:  J Clin Oncol       Date:  1983-02       Impact factor: 44.544

9.  A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate.

Authors:  J H Goldie; A J Coldman
Journal:  Cancer Treat Rep       Date:  1979 Nov-Dec

Review 10.  Chemotherapy of breast cancer: current views and results.

Authors:  G Bonadonna; P Valagussa
Journal:  Int J Radiat Oncol Biol Phys       Date:  1983-03       Impact factor: 7.038
View more
  2 in total

Review 1.  Idarubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer.

Authors:  L M Hollingshead; D Faulds
Journal:  Drugs       Date:  1991-10       Impact factor: 9.546

Review 2.  Mitoxantrone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer.

Authors:  D Faulds; J A Balfour; P Chrisp; H D Langtry
Journal:  Drugs       Date:  1991-03       Impact factor: 9.546
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.